The small, virtual team at Syntimmune bags a $50M round in the march toward a pivotal test
With a pair of Phase Ib/IIa studies underway for its lead drug, the virtual team at Syntimmune now has a $50 million venture round— largely …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
